These findings indicate that, while the blast percentage threshold may no longer serve a diagnostic purpose, higher blast counts within MECOM-rearranged AML are associated with more aggressive disease biology and poorer survival outcomes. The gene discussed is MECOM; the disease is acute myeloid leukemia.